Canada markets closed
  • S&P/TSX

    19,351.32
    +29.42 (+0.15%)
     
  • S&P 500

    4,185.47
    +15.05 (+0.36%)
     
  • DOW

    34,200.67
    +164.68 (+0.48%)
     
  • CAD/USD

    0.7996
    +0.0020 (+0.25%)
     
  • CRUDE OIL

    63.07
    -0.39 (-0.61%)
     
  • BTC-CAD

    75,784.96
    -1,992.10 (-2.56%)
     
  • CMC Crypto 200

    1,398.97
    +7.26 (+0.52%)
     
  • GOLD FUTURES

    1,777.30
    +10.50 (+0.59%)
     
  • RUSSELL 2000

    2,262.67
    +5.60 (+0.25%)
     
  • 10-Yr Bond

    1.5730
    +0.0430 (+2.81%)
     
  • NASDAQ

    14,052.34
    +13.58 (+0.10%)
     
  • VOLATILITY

    16.25
    -0.32 (-1.93%)
     
  • FTSE

    7,019.53
    +36.03 (+0.52%)
     
  • NIKKEI 225

    29,683.37
    +40.68 (+0.14%)
     
  • CAD/EUR

    0.6670
    +0.0012 (+0.18%)
     

Breast Cancer Diagnostics Market Research Report by Type, by Technique, by End-user - Global Forecast to 2025 - Cumulative Impact of COVID-19

ReportLinker
·5 min read

Breast Cancer Diagnostics Market Research Report by Type (Biopsy, Blood Tests, Genomic Tests, and Imaging), by Technique (Imaging, Molecular Testing, and Tissue Biopsy Tests), by End-user - Global Forecast to 2025 - Cumulative Impact of COVID-19

New York, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Breast Cancer Diagnostics Market Research Report by Type, by Technique, by End-user - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05993440/?utm_source=GNW

Market Statistics:
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.

1. The Global Breast Cancer Diagnostics Market is expected to grow from USD 5,286.71 Million in 2020 to USD 7,431.94 Million by the end of 2025.
2. The Global Breast Cancer Diagnostics Market is expected to grow from EUR 4,635.48 Million in 2020 to EUR 6,516.46 Million by the end of 2025.
3. The Global Breast Cancer Diagnostics Market is expected to grow from GBP 4,120.95 Million in 2020 to GBP 5,793.15 Million by the end of 2025.
4. The Global Breast Cancer Diagnostics Market is expected to grow from JPY 564,225.92 Million in 2020 to JPY 793,176.32 Million by the end of 2025.
5. The Global Breast Cancer Diagnostics Market is expected to grow from AUD 7,677.00 Million in 2020 to AUD 10,792.16 Million by the end of 2025.

Market Segmentation & Coverage:
This research report categorizes the Breast Cancer Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Type, the Breast Cancer Diagnostics Market studied across Biopsy, Blood Tests, Genomic Tests, and Imaging.

Based on Technique, the Breast Cancer Diagnostics Market studied across Imaging, Molecular Testing, and Tissue Biopsy Tests. The Imaging further studied across Analog Mammography, Breast Ultrasound System, Digital Mammography, Mammography, MRI Scan, and PET/CT Scan.

Based on End-user, the Breast Cancer Diagnostics Market studied across Diagnostic Laboratories, Hospitals & Ambulatory Surgery Center, and Research & Academic Institutes.

Based on Geography, the Breast Cancer Diagnostics Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Breast Cancer Diagnostics Market including Abbott Laboratories, Agilent Technologies, Inc., Ascenda BioSciences LLC, AstraZeneca, PLC, Becton, Dickinson, and Company, Bio-Rad Laboratories, Inc, Biocept, Inc., BioNTech SE, C.R. Bard, Inc., Danaher Corporation, Epigenomics Inc, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings Corporation, GE Healthcare, Genomic Health, Hologic Inc., Illumina, Inc., Koninklijke Philips N.V., Leica Biosystems, Myriad Genetics, Inc., NanoString Technologies, Inc, Paragon Biosciences LLC, Questex LLC, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Todos Medical, and Toshiba Corporation.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Breast Cancer Diagnostics Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Breast Cancer Diagnostics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Breast Cancer Diagnostics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Breast Cancer Diagnostics Market?
4. What is the competitive strategic window for opportunities in the Global Breast Cancer Diagnostics Market?
5. What are the technology trends and regulatory frameworks in the Global Breast Cancer Diagnostics Market?
6. What are the modes and strategic moves considered suitable for entering the Global Breast Cancer Diagnostics Market?
Read the full report: https://www.reportlinker.com/p05993440/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001